Home  »  Trading Directions   »  Impel NeuroPharma Inc. (IMPL) stock plunged at las...

Impel NeuroPharma Inc. (IMPL) stock plunged at last close, followed by no current update.

Impel NeuroPharma Inc. (NASDAQ: IMPL) stock declined by 0.79% at the last close.  Impel NeuroPharma is a commercial-stage pharmaceutical firm focused on discovering innovative medicines for people suffering from illness with significant unmet medical needs, with a major emphasis on central nervous system ailments.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


IMPL stock’ Past Development

On Nov 15, 2021, Impel announced its financial results for the third quarter of 2021. Given below are the highlights:

  • In the third quarter of 2021, R&D expenses were $5.9 million, compared to $6.1 million in the third quarter of 2020. The drop in R&D investment was mostly due to lower clinical costs for Trudhesa as the Phase 3 study came to an end.
  • SG&A expenses were $16.3 million in the third quarter of 2021, compared to $2.9 million in the third quarter of 2020. The rise in SG&A was primarily attributable to increased spending to support commercial and marketing preparations for the Trudhesa launch.
  • Impel recorded a net loss of $25.0 million in Q3 of 2021, whereas the net loss was $9.2 million in the third quarter of 2020.
  • In the third quarter of 2021, GAAP Net Loss per Share was $1.24 per share, compared to $15.56 in the third quarter of 2020.
  • In the third quarter of 2021, non-GAAP Net Loss per Share was $1.23, compared to $0.49 in the third quarter of 2020.
  • The company had $111.3 million in cash and cash equivalents as of September 30, 2021.

Adrian Adams, Chairman and CEO of Impel NeuroPharma commented that,

The third quarter was genuinely transformative for Impel, with the licensing and timely release of Trudhesa. Since their commercial release in early October, they’ve been ecstatic with the early uptake and prescription trends they’ve seen in the market. They are convinced that Impel’s improved balance sheet will give them the funds they need to maintain the successful commercialization of Trudhesa given the recent follow-on equity offering. It will also aid in the development of INP105 for the cure of agitation and violence in people with autism.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

Sign up for Our Newsletter Now! Discover which stocks to trade!
100% Free. Stop Anytime. No Spam